American Century Companies’s Enliven Therapeutics ELVN Stock Holding History

American Century Companies's ELVN Position: Q2 2026 in Review

American Century Companies increased its Enliven Therapeutics (ELVN) stake by 811% in Q2 2026, buying an estimated $21.4M and bringing the position to 566,165 shares worth $28.7M. The position accounts for 0.01% of the portfolio, ranked #1108.

American Century Companies first reported a position in ELVN in Q1 2024 and has held it in 6 quarters since. 121 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

• American Century Companies held 566,165 shares of Enliven Therapeutics worth $28.7M as of Q2 2026.
• American Century Companies bought 504,049 Enliven Therapeutics shares in Q2 2026, an estimated $21.4M.
• Enliven Therapeutics made up 0.01% of American Century Companies's portfolio in Q2 2026, its #1108 holding.
• American Century Companies first reported a position in Enliven Therapeutics in Q1 2024 and has held it in 6 quarters since.
• 121 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.